Abstract 350P
Background
The diagnosis and treatment of breast cancer involves changes in personal, family, social, professional and sexual relationships. In this study we assessed sexual satisfaction in patients with early breast cancer using the validated SEXSAT-Q scale.
Methods
We used the SEXSAT-Q quality of life questionnaire in 60 patients diagnosed with early breast cancer at our centre. Six dimensions were studied: 1. Loss of sexual desire. 2. Alteration of body image. 3. Psychological coping. 4. Discomfort during sexual intercourse. 5. Satisfaction during sexual intercourse. 6. Satisfaction with breast reconstruction. Data were collected in Medical Oncology Department during March 2023.
Results
A sample of 60 patients was selected, aged 26-72 years old, with a median age of 52 years, who had undergone breast cancer surgery, 73.33% by conservative surgery. 20% were premenopausal, 10% were perimenopausal and 70% were menopausal. 35% were being treated with chemotherapy, 56.67% with hormonoterapy and 8.33% with anti-HER2. 78.33% had a stable partner and did not use contraception. 30% of patients were quite or very sad and depressed since starting treatment. 50% of patients believe that the treatment has worsened their body image. 75% reported that during treatment their sexual relations were not satisfactory. 61.67% believe that their sexual desire has decreased and 45% admit having more problems reaching orgasm since diagnosis.
Conclusions
Women with curable breast cancer it is important to know the impact of diagnosis and treatment on the sexual sphere. The SEXSAT-Q questionnaire is a validated scale capable of measuring the sexual satisfaction of our patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M.L. Garrido Onecha.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
360P - Neoadjuvant inetetamab combined with pertuzumab, paclitaxel and carboplatin for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study
Presenter: Yue Chai
Session: Poster session 03
361P - A phase II study of fulvestrant combined with chemotherapy in the neoadjuvant treatment of HR+/HER2- locally advanced breast cancer
Presenter: Jing Wu
Session: Poster session 03
362P - CYBERNEO trial: Update of results at 14 years of follow-up
Presenter: Syrine Ben Dhia
Session: Poster session 03
363P - High adipocytokines and IL-18bp serum levels are associated with lower objective response rate after neoadjuvant treatment in breast cancer patients with metabolic syndrome
Presenter: Larissa Mont'Alverne Arruda
Session: Poster session 03
365P - Effectiveness and safety of human type 5 recombinant adenovirus (H101) in malignant tumor with malignant pleural effusion and ascites: A multicenter, observational, real-world study
Presenter: Baocheng Wang
Session: Poster session 03
366P - Artificial intelligence (AI)-powered assessment of complete and intense human epidermal growth factor receptor 2 (HER2)-positive tumor cell proportion in breast cancer: Predicting fluorescence in situ hybridization (FISH) positivity and response to HER2-targeted therapy
Presenter: Minsun Jung
Session: Poster session 03
367P - Sentinel lymph node biopsy (SLNB) in patients with locally advanced breast cancer (LABC): Descriptive, inferential and survival analysis
Presenter: Johanna Espejo Niño
Session: Poster session 03
368P - Impact of PET-CT-determined sarcopenia on survival and pathological complete response in breast cancer patients with neoadjuvant chemotherapy
Presenter: Gözde Tahtaci
Session: Poster session 03
369P - The impact of germline BRCA mutations in locally advanced, triple-negative breast cancer (TNBC) treated with platinum- based neoadjuvant chemotherapy
Presenter: Hadar Goldvaser
Session: Poster session 03
370P - LYMPHA surgery to reduce lymphedema following axillary node clearance: A new study at a London plastics centre
Presenter: Dorian Hobday
Session: Poster session 03